Stockscreener 앱 받기
169.41
1.02%
-1.75
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz sells priority review voucher for $200 million - First Word Pharma
JAZZ: Sharpened rare disease focus, record growth, and pivotal zanidatamab results drive future milestones - TradingView — Track All Markets
JAZZ: Rare disease focus, record revenues, and zanidatamab's breakthrough in GEA drive future growth - TradingView — Track All Markets
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth - TradingView — Track All Markets
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC - MarketBeat
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham - Yahoo Finance
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com Nigeria
Jazz Pharmaceuticals stock price target raised to $230 by Truist Securities - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ): Truist Securities Boosts Price Targ - GuruFocus
Truist Financial Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Jazz Pharmaceuticals plcExpects to meet 2025 revenue guidanceSEC filing - marketscreener.com
Jazz Pharmaceuticals PLCExpects To Meet 2025 Revenue GuidanceSEC Filing - TradingView — Track All Markets
Jazz Pharmaceuticals stock price target raised to $235 by Needham - Investing.com Nigeria
Boehringer and Jazz to test HER2-positive breast cancer combo therapy - Investing.com UK
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - The Manila Times
What Analysts Are Saying About Jazz Pharmaceuticals Stock - Benzinga
Needham Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $235 | JAZZ Stock News - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain - Yahoo Finance
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year? - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - sharewise.com
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 - MarketBeat
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 DataHas The Bull Case Changed? - simplywall.st
Lecap Asset Management Ltd. Buys Shares of 6,319 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB - MarketBeat
Robeco Institutional Asset Management B.V. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz pharmaceuticals appoints Thomas Riga as chief business officer - Investing.com
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - marketscreener.com
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Is Jazz Pharmaceuticals plc stock positioned well for digital economyInstitutional Holding Changes & Free Stop-Loss Planning for Your Portfolio - ulpravda.ru
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer, Effective January 1, 2026 - marketscreener.com
Why Is Jazz Pharmaceuticals Stock Trading Higher Today?Jazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
Jazz’s Ziihera Stakes Claim As Frontline Choice In HER2+ Gastroesophageal Cancer - Citeline News & Insights
Jazz data not music to investors’ ears - The Pharma Letter
Jazz Pharmaceuticals stock shows promise with positive Phase 3 data By Investing.com - Investing.com Nigeria
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz boasts of first-line Ziihera data in gastroesophageal cancers - MSN
Jazz Pharmaceuticals stock falls after Phase 3 trial results By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals stock falls after Phase 3 trial results - Investing.com
4.73%
0.92%
자본화:
|
볼륨(24시간):